According to the latest data from Mi Nei.
com, in the first half of 2021, the sales of terminal antidepressant drugs in China's public medical institutions declined slightly year-on-year
.
From the perspective of the manufacturer's structure, the TOP3 "iron triangle" composed of Pfizer, Eli Lilly, and Lingbei has been broken for many years.
Shantouwei Pharmaceutical has entered the top three, Chengdu Kanghong Pharmaceutical has risen to the fourth place, and Jiangsu Hausen The market share of domestic pharmaceutical companies such as Pharmaceutical and Sichuan Kelun Pharmaceutical has increased rapidly
.
At present, 18 antidepressants have been reviewed, and after 8 varieties have been included in the collection, the market has entered a reshuffle period
.
There are 16 products under review, including Luye Pharma’s Class 1 new drug Ansulfaxine Hydrochloride Sustained-release Tablets.
In addition, Futhiaxetine Hydrobromide Tablets are the most sought-after; Escitalopram oxalate oral solution, No company has been approved for products such as desvenlafaxine succinate sustained-release tablets and fluoxetine hydrochloride oral solution, involving Chengdu Kanghong Pharmaceutical | Chengdu Dikang Pharmaceutical, Zhejiang Jianfeng Pharmaceutical, Yichang Renfu Pharmaceutical, etc.
Businesses
.
The ranking of TOP10 antidepressants has changed! Pfizer, Eli Lilly , and Lingbei "iron triangle" are broken
Sales of terminal antidepressant drugs in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
Depression is a common mental illness, and it has become a major public health and social problem
.
According to the latest WHO data, there are approximately 280 million people suffering from depression in the world.
Therefore, the antidepressant market has a huge space.
In China, public medical institutions are the main sales channel for antidepressants
.
The latest data from Minai.
com shows that in the first half of 2021, the sales of terminal antidepressant drugs in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) declined slightly year-on-year
.
From the perspective of the sales structure of manufacturers, the TOP3 "iron triangle" situation composed of Pfizer, Eli Lilly and Ling Bei has been broken for many years, and the total market share has fallen from more than 35% in 2020 to 26% in the first half of 2021.
3 All companies have declined, among which Eli Lilly fell to fifth place
.
It is worth noting that with the normalization of centralized procurement and the continued efforts of domestic pharmaceutical companies, in the first half of this year, Shantou Medical Pharmaceutical has entered the top three, Chengdu Kanghong Pharmaceutical has risen to fourth place, and Jiangsu Haosen Pharmaceutical, The market share of domestic pharmaceutical companies such as Sichuan Kelun Pharmaceutical is also rising rapidly
.
2021H1 TOP10 Terminal Antidepressant Drug Products in Public Medical Institutions in China
Source: Terminal competition landscape of China's public medical institutions
The sales of TOP10 products all exceeded 100 million yuan, and escitalopram oxalate tablets still ranked first
.
In terms of growth rate, agomelatine tablets were the fastest, exceeding 90%, and both venlafaxine hydrochloride sustained-release tablets and trazodone hydrochloride tablets exceeded 20%
.
In the five batches of centralized procurement carried out by the country, a total of 8 antidepressants have been included, including escitalopram oxalate tablets, sertraline hydrochloride tablets, duloxetine hydrochloride enteric-coated capsules, and paroxetine hydrochloride tablets , Venlafaxine Hydrochloride Sustained-Release Capsules and Venlafaxine Hydrochloride Sustained-Release Tablets are among the top 10 terminal antidepressant products in China's public medical institutions in the first half of 2021
.
Except for the two varieties of venlafaxine hydrochloride sustained-release capsules and venlafaxine hydrochloride sustained-release tablets, which have just begun to land in the fifth batch of centralized procurement, only escitalopram oxalate tablets (4+7, expanded centralized procurement) ) Is a positive growth.
Under the siege of domestic pharmaceutical companies such as Shantouwei Pharmaceutical, Sichuan Kelun Pharmaceutical, Hunan Dongting Pharmaceutical, the original research company Lingbei's market share has declined rapidly, from more than 35% in 2019 to the first half of 2021.
25 %
.
Sertraline hydrochloride tablets (the third batch of centralized procurement) is the variety with the largest decline.
Although Pfizer’s market share still ranks first, it has fallen from more than 70% in 2020 to 56% in the first half of 2021.
Zhejiang Huahai Pharmaceutical The market share of two bid-winning companies, Zhejiang Jingxin Pharmaceutical and Zhejiang Jingxin Pharmaceutical, has risen rapidly.
Among them, Zhejiang Huahai Pharmaceutical has increased from less than 10% in 2020 to more than 20% in the first half of 2021
.
In the domestic antidepressant market, due to the early entry of original research drugs, the top position has been occupied by foreign pharmaceutical companies for many years
.
With the expiration of patents of original research drugs and the implementation of policies such as centralized procurement and medical insurance negotiations, domestic companies have gradually increased their layout in the antidepressant market.
Especially after centralized procurement, the process of domestic substitution will be further promoted, and the market structure will be Will change
.
18 antidepressants have been reviewed, Fosun, Kelun.
.
.
lead the way
Antidepressant product over-evaluation status
Source: One-key search on Mynet, MED2.
0 Chinese Drug Evaluation Database
Up to now, a total of 18 antidepressants have been reviewed.
Among them, escitalopram oxalate tablets, duloxetine hydrochloride enteric-coated capsules, and paroxetine hydrochloride tablets are the most popular products.
The number of reviewed companies is 9 and 8 respectively.
Home, 5 homes
.
In addition, only one company has reviewed 9 products, including Futhiaxetine hydrobromide tablets from CP Tianqing Pharmaceutical Group, Citalopram Hydrobromide Capsules from Kelun, and Livzon Pharmaceutical Factory of Livzon Group.
fluvoxamine maleate tablets, bupropion hydrochloride Humanwell Pharmaceutical bupropion sustained release tablets (ⅱ) and the like
.
In terms of the number of products reviewed, Fosun Pharma, Kelun Pharmaceutical, and Huahai Pharmaceutical lead the way
.
Fosun Pharma has the most, and its subsidiaries Chongqing Yaoyou Pharmaceutical and Hunan Dongting Pharmaceutical have each reviewed two products; followed by Kelun Pharmaceutical and Huahai Pharmaceutical each have three products reviewed
.
16 antidepressants are under review! Luye Class 1 new drugs, Renfu, Kanghong.
.
.
heavy new products are coming
Status of antidepressant drugs reported for production and under review since 2019
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
Since 2019, a total of 16 antidepressant drugs have been reported for production and are under review and approval.
Among them, vothiaxetine hydrobromide tablets are the most sought-after, with as many as 10 application acceptance numbers, involving Yangzijiang Pharmaceutical Group and Jiangsu Hausen Pharmaceutical industry, Europa CSPC Pharmaceutical, Chengdu Brilliant Pharmaceutical and other companies
.
In July this year, Chia Tai Tianqing Pharmaceutical Group won the first imitation + first review of the product.
Before that, there was only one domestic manufacturer in the original Lingbei
.
According to data from Meinenet, the sales of terminal vothiaxetine hydrobromide tablets in public medical institutions in China in the first half of 2021 are close to the full-year level of 2020, a year-on-year increase of 129.
36%
.
Ansufaxine Hydrochloride Sustained-Release Tablets is a new class 1 drug developed by Luye Pharma, and a new antidepressant drug developed based on its new therapeutic entity/new molecular entity (NTE/NCE) technology platform
.
According to data, in March this year, Luye Pharma’s new compound (NCE) and Ansufaxine Hydrochloride Sustained Release Tablets (LY03005) in the China III clinical trial for the treatment of depression (MDD) reached the preset end point; in June, LY03005’s The listing application was accepted by CDE
.
In addition, escitalopram oxalate oral solution, desvenlafaxine succinate sustained-release tablets, fluoxetine hydrochloride oral solution and other products have not been approved by enterprises, involving Chengdu Kanghong Pharmaceutical | Chengdu Dikang Pharmaceutical, Zhejiang Guojing Pharmaceutical, Zhejiang Jianfeng Pharmaceutical, Yichang Renfu Pharmaceutical and many other companies
.
Source: Mi Neiwang database
